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Edited by Judit Ova´diAbstract We tested the hypothesis that activation of the polyol
pathway and protein kinase C (PKC) during diabetes is due to
loss of NO. Our results show that after 4 weeks of streptozoto-
cin-induced diabetes, treatment with L-arginine restored NO lev-
els and prevented tissue accumulation of sorbitol in mice, which
was accompanied by an increase in glutathiolation of aldose
reductase. L-Arginine treatment decreased superoxide genera-
tion in the aorta, total PKC activity and PKC-bII phosphoryla-
tion in the heart, and the plasma levels of triglycerides and
soluble ICAM. These data suggest that increasing NO bioavail-
ability by L-arginine corrects the major biochemical abnormali-
ties of diabetes.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Chronic metabolic changes caused by diabetes establish an
inﬂammatory state, accelerate atherogenesis, and increase the
risk of cardiovascular fatality [1,2]. Cellular studies show that
exposure to high glucose induces several metabolic abnormal-
ities that include an increase in the activity of the polyol path-
way, activation of protein kinase C (PKC), and the generation
of reactive oxygen species (ROS) [3]. Of these, activation of the
polyol pathway is a key metabolic alteration, which appears to
be upstream of PKC and ROS, because inhibition of aldose
reductase (AR), an enzyme that catalyzes the ﬁrst and the
rate-limiting step of the polyol pathway, prevents PKC activa-
tion and ROS generation [4]. Another major biochemical alter-
ation during diabetes is a decrease in NO bioavailability. Total
vascular production of NO is decreased in diabetes [1,2] and
gene transfer of endothelial NOS [5] or overexpression of
GTP cyclohydrolase I [6], which generates the NOS cofactor,
tetrahydrobiopterin, diminishes type 1 diabetes (T1D)-induced
endothelial dysfunction. Nevertheless, the relationship be-
tween NO and the metabolic abnormalities due to AR, PKC,
and ROS remains unclear. In vitro, nitrosoglutathione inhibits*Corresponding author. Address: University of Louisville, Division of
Cardiology, Department of Medicine, Delia Baxter Building, 580
South Preston Street, Room 421F, Louisville, KY 40202, United
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doi:10.1016/j.febslet.2008.06.039AR by inducing S-glutathiolation of the protein [4]. Thus, NO
could potentially regulate biochemical pathways of diabetic in-
jury by inhibiting AR. The in vivo validity of this regulatory
axis, however, has not been tested.
We hypothesized that in diabetic animals, increasing NO
production by L-arginine treatment would inhibit AR and
the downstream events leading to PKC activation and ROS
production. Treatment with L-arginine has been shown before
to regulate hyperglycemia and dyslipidemia [7] and inhibit the
polyol pathway [8] in diabetic rats. To examine the eﬀects of L-
arginine, we used a streptozotocin (STZ) model of diabetes to
examine how an increase in NO bioavailability would aﬀect the
major biochemical defects induced by high glucose. Our results
show that treatment with L-arginine increased S-glutathiola-
tion of AR in diabetic animals and that this was associated
with a decrease in sorbitol accumulation, PKC-b activation,
and ROS generation. These ﬁndings reveal a novel regulatory
pathway in which NO acts as a negative regulator of metabolic
abnormalities induced by diabetes.2. Materials and methods
2.1. Animal studies
Male C57BL/6 mice were obtained from Jackson Labs at 6 weeks of
age. Mice were injected (i.p.) with a single dose of approximately
165 mg/kg STZ or an equal volume of 0.05 mol/l citrate buﬀer, pH
4.5 [6]. Blood glucose was measured 3 days after injection using a
HemoCue blood glucose analyzer. Only animals with a blood glucose
>400 mg/dl were included in the study. No animals died during the
procedure. After 2 weeks of hyperglycemia, mice were implanted with
subcutaneous osmotic pumps under anesthesia induced by 300 mg/kg
avertin. The pumps delivered either sterile saline or L-arginine at a
dose of 50 mg/kg/day. The mice were fed a normal chow diet for an
additional 2 weeks. All animals were treated according to institutional
guidelines.
2.2. Measurement of NOx, plasma lipids, sICAM, and TNF-a
Plasma levels of NOx were measured using the Greiss method. Plas-
ma triglycerides were measured using Wako L Type TG H ELISA kits.
Lipoprotein particle size was measured by NMR analysis (LIPO-
SCIENCE, Raleigh, NC). Mouse sICAM was measured by ELISA
(Amersham). Plasma TNF-a was measured using the Mouse TNF-a
Ready-SET-go ELISA kit (eBioscience Inc.).
2.3. Measurement of superoxide generation
Superoxide production in sections of mouse aorta was detected
using dihydroethidium (DHE) as previously described [9]. Fluorescent
images were acquired with a Zeiss LSM 500 microscope and ﬂuores-
cent intensity was quantiﬁed using the MetaMorph software (Univer-
sal Imaging).ation of European Biochemical Societies.
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Membrane-bound PKC activity was measured using the Promega
SignaTECT PKC assay system. The extent of PKC-bII phosphoryla-
tion was measured by Western blot using antibodies that speciﬁcally
recognize phosphorylation of threonine 641 (AbCam). For normaliza-
tion, the blot was stripped and reprobed with antibodies that recognize
total PKC-bII (Santa Cruz Biotechnology).
2.5. Measurement of sorbitol and AR glutathiolation
Sorbitol was measured by gas chromatography [8]. The sorbitol
peak was conﬁrmed by mass spectrometry. AR was immunoprecipi-
tated from heart tissue using polyclonal anti-AR antibodies. Glutathi-
olation of AR was measured by Western analysis using anti-PSSG
antibodies (Virogen, Cambridge, MA).
2.6. Data and statistical analysis
Data are presented as mean ± S.E.M. and the P values were deter-
mined using the unpaired students t-test.0.0
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Fig. 1. L-Arginine prevents diabetic activation of AR and increases
AR glutathiolation in the heart. (A) Sorbitol content was measured by
gas chromatography in kidneys of non-diabetic and diabetic mice.
Data are presented as mean ± S.E.M., *P < 0.001 versus STZ, n = 5–7
per group. (B) AR glutathiolation was assessed by immunoprecipita-
tion of AR from ventricular tissue followed by immunoblotting with
anti-PSSG antibodies. Inset shows Western blots representative of
three to four individual experiments. Data are presented as mean ±
S.E.M., *P < 0.05 versus control, n = 3–4 per group.3. Results
3.1. L-Arginine increases NO production in hyperglycemic mice
Four weeks after STZ treatment, there was no change in
heart weight or heart/body weight ratios in mice treated with
saline or L-arginine (Table 1). Non-fasting blood glucose was
signiﬁcantly increased in STZ-treated mice. Although L-argi-
nine has been reported to protect rat b-cells against the diabe-
togenic eﬀects of alloxan [10], in our study, blood glucose levels
were not aﬀected by L-arginine treatment. High levels of NOx
were measurable in untreated mice; however, the levels of NOx
in the plasma of STZ-treated mice were undetectable. L-Argi-
nine restored plasma NOx production to a level not signiﬁ-
cantly diﬀerent than non-diabetic animals (Table 1).
3.2. L-Arginine induces glutathiolation of AR and abolishes
hyperglycemia-induced increases in sorbitol accumulation
Upon comparison with non-diabetic mice, a 5.8-fold increase
in renal sorbitol level was observed in diabetic mice, indicating
an increase in AR mediated reduction of glucose. No change in
AR protein levels was observed (data not shown). Accumula-
tion of sorbitol in diabetic animals was completely abolished
by L-arginine (Fig. 1A), indicating that L-arginine inhibits the
polyol pathway. L-Arginine treatment in diabetic animals also
induced a marked increase in AR glutathiolation compared
with diabetic hearts from mice treated with saline (Fig. 1B).
The extent of AR glutathiolation induced by L-arginine was
greater in STZ-treated animals than in control (non-diabetic)
animals (Fig. 1B), indicating that AR in diabetic tissues is more
susceptible to glutathiolation.
3.3. L-Arginine prevents PKC activation in the diabetic heart
Diabetic hearts displayed a 2.2-fold higher level of mem-
brane-associated PKC activity than non-diabetic heartsTable 1
Physical parameters of study animals
Control S
Heart weight (g) 22.9 ± 0.43 2
Heart/body ratio (mg/g) 4.96 ± 1.9 4
Blood glucose (mg/dl) 258 ± 27 >
NOx (nitrate + nitrite) (micromol/l) 918 ± 386 N
Blood glucose levels were measured in non-fasting animals. Plasma NOx leve
ﬁltered to remove all proteins above 10 kDa. NOx were not detectable (ND) in(Fig. 2A). There was signiﬁcantly greater PKC-bII phosphory-
lation in diabetic hearts than the non-diabetic controls. PKC-
bII activation in diabetic hearts was abolished by L-arginine
treatment (Fig. 2B).
3.4. L-Arginine decreases vascular superoxide generation
STZ-induced diabetes was associated with a signiﬁcant in-
crease in dihydroethidium (DHE) staining of aorta. Compared
with non-diabetic controls, a 6.2 ± 1.6-fold increase in ﬂuores-TZ Control + L-arg STZ + L-arg
1.1 ± 0.51 23.6 ± 0.55 17.8 ± 0.12
.47 ± 1.4 4.63 ± 1.7 4.91 ± 2.8
400 278 ± 29 >400
D 3030 ± 1910 368 ± 81.0
ls were measured by colorimetric reaction in plasma samples that were
plasma from diabetic mice (STZ). Values are mean ± S.E.M., n = 5–8.
ph
os
ph
o-
PK
C
 β I
I/t
ot
al
 P
KC
 β I
I
0.0
0.5
1.0
1.5
2.0
2.5
     Control      + L-arg           Control       + L-arg
To
ta
l P
KC
 a
ct
iv
ity
 (p
m
ol
/m
in
/μ
g 
pr
ot
ei
n)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Control         STZ          Control         STZ    
+ L-arginine 
*
**
Phospho-PKC-
PKC-βII
βII
+ L-arg
*
**
STZ
Fig. 2. L-Arginine supplementation abolishes diabetes induced PKC
activation. (A) Membrane-bound total PKC activity in ventricular
tissue from mouse hearts was measured and normalized to total
protein. Data are presented as mean ± S.E.M., *P < 0.002 versus
control, **P < 0.002 versus STZ, n = 3 per group. (B) PKC-bII
phosphorylation was measured by Western blot analysis in mouse
hearts and normalized to total PKC-bII in the same blot after stripping
and reprobing. Data are presented as mean ± S.E.M., *P < 0.05 versus
control; **P < 0.01 versus STZ, n = 3–4 per group.
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niﬁcantly decreased DHE staining compared with saline-trea-
ted diabetic animals (Fig. 3B).
3.5. L-Arginine prevents diabetic dyslipidemia
Diabetic mice displayed 2- to 2.4-fold higher levels of plasma
triglyceride than non-diabetic controls. L-Arginine treatment
reduced plasma triglycerides in diabetic animals to levels not
signiﬁcantly diﬀerent from those of non-diabetic animals
(Fig. 4A). No diﬀerences in total cholesterol were observed
(Fig. 4B). NMR analysis revealed that L-arginine treatment
signiﬁcantly decreased triglycerides associated with VLDL
(40.9 ± 12.9 mg/dl versus 17.3 ± 14.6 mg/dl; P < 0.05), which
was associated with a slight, but statistically insigniﬁcant de-
crease in VLDL particle concentration. No signiﬁcant changes
in VLDL particle size was observed, although the concentra-
tion of large VLDL was decreased from 3.07 ± 1.7 to
0.52 ± 0.3 nmol/l (P < 0.05).3.6. L-Arginine diminishes vascular inﬂammation
Vascular inﬂammation, as assessed by an increase in the cir-
culating levels of soluble intercellular adhesion molecule (sI-
CAM), is increased in T1D [11]. In STZ-treated mice, we
observed a modest but signiﬁcant increase (1.3-fold versus con-
trol) in sICAM levels. This increase in sICAM was completely
abolished by L-arginine (Fig. 5), suggesting that L-arginine
prevents endothelial activation. L-Arginine treatment did not
signiﬁcantly change circulating TNF-a. Lower levels of plasma
TNF-a were observed in diabetic animals treated with L-argi-
nine than either non-diabetic or untreated diabetic animals,
although the diﬀerence was not statistically signiﬁcant (data
not shown).4. Discussion
The results of this study show that L-arginine treatment
ameliorates vascular inﬂammation and diabetic dyslipidemia
in a murine T1D model. Treatment with L-arginine markedly
prevented tissue sorbitol accumulation, ROS generation, and
PKC activation – three critical biochemical abnormalities
associated with hyperglycemic injury. Taken together, these re-
sults support the novel concept that NO is an endogenous neg-
ative regulator of the AR–PKC–ROS pathway and therefore a
decrease in NO production or availability during diabetes is a
key step that is mechanistically linked to the major biochemi-
cal eﬀects of high glucose. It follows that increasing NO syn-
thesis by L-arginine could prevent oxidative stress and
inﬂammation by restoring the regulatory axis of NO that con-
trols glucose metabolism via AR and the downstream activa-
tion of PKC and ROS production.
Changes in NO signaling and production profoundly aﬀect
cardiovascular disease [12,13]. Indeed, a decrease in NO has
been suggested to be the underlying mechanism common to
all major CVD risk factors such as high cholesterol, hyperten-
sion, and smoking [12,13]. Diabetes is associated with pro-
found impairment of NO production and signaling. The
insulin-resistant state of T2D is associated with marked endo-
thelial dysfunction, which has been variably linked to a de-
crease in NO synthesis or NO bioavailability [1,2]. Diabetes
has also been associated with increased NOS uncoupling lead-
ing to superoxide generation [14]. It is likely that the role of
NO in regulating CVD and cardiovascular complications of
diabetes is complex and depends on disease stage and dura-
tion. Hence, for mechanistic understanding and therapeutic
strategizing, it is essential to demarcate how the role of NO
evolves and varies with disease progression and how disrup-
tions in NO production and signaling can be restored.
Accordingly, in the current study, we examined the earliest
stages of T1D, before the development of overt tissue injury
(e.g., endothelial dysfunction), but when the biochemical
changes are fully manifest. Targeting early stages of the disease
is important, because during later stages of the disease,
changes due to evolving systemic inﬂammation, insulin resis-
tance and dyslipidemia become circuitous, making it diﬃcult
to separate causes from eﬀects. In particular, the synergistic ef-
fect of glucotoxicity and lipotoxicity become diﬃcult to disen-
tangle. However, as shown by the current study, during early
stages of the disease, the biochemical changes are mainly due
to high glucose and largely correctable by increasing NO.
Although speciﬁc mechanisms of early NO deﬁciency remain
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Fig. 3. L-Arginine supplementation decreases superoxide production in diabetic aorta. Sections (30 lm) of aorta from diabetic and non-diabetic mice
were incubated with DHE to measure the abundance of superoxide. Panel A shows representative staining in aorta from control or diabetic animals
(STZ) supplemented without or with L-arginine for 2 weeks (+L-arginine). (B) Fluorescent intensity was quantiﬁed using MetaMorph software. Plot
represents fold-increase in thresholded area versus appropriate control. Data are presented as mean ± S.E.M., *P < 0.05 versus control; **P < 0.01
versus STZ, n = 5–9 animals per group.
2612 M.B. West et al. / FEBS Letters 582 (2008) 2609–2614unclear (see below), the observation that biochemical changes
due to high glucose were overcome by L-arginine treatment
suggests that the decrease in NO bioavailability is not due to
BH4 deﬁciency. Moreover, the defect does not appear to be
due to NOS uncoupling, because if this was so, then providing
more substrate would have increased (rather than decreased)
ROS production. Instead, it appears that the decrease in NO
is due to its excessive utilization by increased ROS. This is con-
sistent with the marked increase in superoxide generation in
diabetic vessels, which depends upon the stimulation of several
pathways including AR and PKC.
Previous studies with cells cultured in high glucose and STZ-
treated rats show that the major pathways aﬀected by high glu-
cose are PKC [15] and AR [4]. High glucose and diabetes also
lead to excessive accumulation of advanced glycosylation end
products (AGEs) [3]. This, however, is a late phenomenon.In the current study we found that although sorbitol accumu-
lation and PKC activity were increased in mice within 4 weeks
of STZ treatment, no signiﬁcant accumulation of AGEs was
found in the heart (data not shown). In tissues in which glucose
transport is not regulated by insulin (e.g., endothelium, nerve,
kidney), glucose, at concentrations exceeding the glycolytic
capacity, is metabolized via AR to sorbitol, which is further
converted to fructose by sorbitol dehydrogenase [4]. The activ-
ity of the polyol pathway, in particular AR has been linked to
several cell functions. It has been shown that inhibition of the
enzyme prevents SMC growth, endothelial activation and
adhesion, and inﬂammation resulting from the activation of
NF-jB and AP-1 [4]. Signiﬁcantly, inhibition of AR prevents
high glucose-induced DAG formation and the activation of
multiple PKC isoforms, including PKC-bII [16]. Our previous
work shows that NO inhibits AR activity by inducing the for-
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measured as described. Data are presented as mean ± S.E.M.,
*P < 0.0005 versus control; **P < 0.05 versus STZ, n = 6–9.
sI
C
AM
 (n
g/
m
l/m
g 
pr
ot
ei
n)
1000
2000
3000
Control       STZ    Control STZ 
*
**
L-arginine
Fig. 5. L-Arginine treatment decreases circulating markers of inﬂam-
mation. Plasma sICAM levels were measured by ELISA and normal-
ized to total protein. Data are presented as mean ± S.E.M., *P < 0.05
versus control; **P < 0.05 versus STZ, n = 5–7 per group.
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teine [4]. We have shown that treatment of diabetic rats with
L-arginine or nitroglycerine inhibits AR activity and prevents
sorbitol accumulation [8]. Consistent with this work, we found
that L-arginine treatment prevents sorbitol accumulation indiabetic mice; however, the current data reveal for the ﬁrst
time that augmenting NO synthesis by L-arginine increases
AR glutathiolation and prevents downstream increase in
ROS generation and PKC activation.
Activation of PKC isoforms, particularly PKC-bII has been
associated with several features of glucose toxicity, including
microvascular changes, increased vascular ROS generation,
and endothelial and macrophage activation [17]. In particular,
hyperglycemia-induced endothelial dysfunction in humans is
prevented by pretreatment with the PKC-bII-speciﬁc inhibitor
– ruboxistaurin [18]. Hence, our observation that increasing
NO by simple L-arginine supplementation prevents PKC acti-
vation supports the unifying hypothesis that AR plays a critical
role in the early stages of diabetic complications and that inhi-
bition of this enzyme by increasing NO prevents one of the ma-
jor causes of diabetic complications, i.e., PKC activation.
We found that murine T1D was associated with an increase
in plasma triglycerides. This is consistent with human data
showing that poorly controlled T1D is associated with hyper-
triglyceridemia [19]. Treatment with L-arginine decreased total
and VLDL-associated triglyceride content, consistent with a
direct eﬀect of NO on VLDL rather than on chylomicron rem-
nants. Decreases in HDL cholesterol content and size were
also observed (data not shown), which may be reﬂective of
reversal of diabetes-induced changes. The decrease in VLDL
triglycerides was; however, associated with a decrease in the
concentration of large VLDL and an increase in IDL concen-
tration. These changes most likely reﬂect a reduction in triglyc-
eride concentration. Hence, the primary eﬀect of L-arginine on
lipoprotein subclasses reﬂects attenuation of hypertriglyceride-
mia. While the mechanisms by which L-arginine (or NO) af-
fects triglyceride metabolism remain unclear, it is signiﬁcant
to point out that unlike L-arginine treatment, overexpression
of GTP cyclohydrolase fails to normalize diabetes induced in-
creases in triglycerides or HDL even though BH4 levels were
restored. Thus, L-arginine supplementation may be an eﬀective
intervention for treating early dyslipidemia in diabetes.
In summary, we have found that L-arginine supplementation
prevents vascular oxidative stress and inﬂammation in a mur-
ine model of T1D diabetes. The results obtained support the
hypothesis that NO is a master regulator of the AR–PKC–
ROS pathway, which is the major mediator of hyperglycemic
injury. Based on these observations, we suggest the L-arginine
treatment (or other modes of increasing NO synthesis) may be
a beneﬁcial clinical intervention to suppress or delay hypergly-
cemic injury at least during the early stages of T1D.
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